NanoViricides, Inc. filings document the formal disclosures of a clinical-stage antiviral drug developer listed on NYSE American under the symbol NNVC. The company’s SEC record covers material events, proxy governance, stockholder voting matters and capital-raising transactions tied to its common stock and other securities.
Recent filings include Form 8-K reports on annual-meeting voting results, a registered direct offering involving common stock and pre-funded warrants, and officer compensation arrangements. Proxy materials describe board elections, advisory compensation votes, auditor ratification and related governance procedures. The filings also identify capital-structure elements such as common stock, Series A convertible preferred stock and shelf-registration-based financing activity.
NanoViricides, Inc. may currently offer and sell common stock through or to D. Boral Capital LLC, as sales agent or principal, for an aggregate offering price of up to $2,374,774 under its at-the-market program.
While its public float remains below $75 million, Form S-3 public primary offerings in any 12-calendar-month period cannot exceed one-third of public float. NanoViricides reported that it had offered and sold approximately $12,012,443 of common stock during the prior 12-calendar-month period ending October 21, 2026.
NanoViricides, Inc. (NNVC) solicits proxies for its November 21, 2026 annual meeting, where stockholders will vote on re-electing Todd E. Rokita, Makarand Jawadekar and Brian Zucker for two-year terms, ratifying EisnerAmper LLP as auditor for the fiscal year ending June 30, 2027, and other business. The board recommends voting FOR each proposal. As of September 21, 2026, the voting pool included 25,439,439 common shares and 918,809 Series A preferred shares, carrying nine votes each, for 33,708,720 total votes.
Related-party disclosures state that TheraCour, whose CEO and director Anil Diwan owns approximately 90% of its capital stock, charged approximately $1,995,000 in development costs for the year ended June 30, 2026, and was owed approximately $829,000 at June 30, 2026. No royalties were due or paid through June 30, 2026. The 2026 compensation table reports total compensation of $440,052 for Anil Diwan and $135,445 for Chief Financial Officer Meeta Vyas.
NanoViricides, Inc. extended President Dr. Anil R. Diwan’s employment agreement for July 1, 2026 through June 30, 2027, with a $400,000 annual base salary. The company granted him 10,204 shares of Series A Preferred Stock, with rights vesting in equal quarterly installments beginning September 30, 2026 and fully vesting June 30, 2027. NanoViricides will maintain a $2 million term life insurance policy, with $1 million assigned to the company and the remaining balance to Dr. Diwan’s estate. If terminated other than for cause, he is eligible for six months of salary severance and benefits during that period.
The company also extended Chief Financial Officer Meeta Vyas’s agreement for one year, through June 30, 2027, with annual renewal. The extension provides for reimbursement of up to 50% of her health-insurance costs, capped at $2,500 per month.
NanoViricides, Inc. (NNVC) described NV-387 development progress. Its completed Phase Ia/Ib study in healthy adults reported no dropouts or adverse events, and the company said the drug was well tolerated at the highest multiple-dose level. Two Phase II studies of oral gummies for Mpox and Ebola were about to start in the Democratic Republic of the Congo under local regulatory approvals, with trial supplies received at both sites. Mpox enrollment and dosing were expected within a few weeks after site preparations were completed.
NanoViricides said it has no customers, products or revenue to date. Research and development expense was approximately $4.708 million for the year ended June 30, 2026, compared with approximately $5.549 million in FY2025. Under its India agreement with Karveer Meditech, NanoViricides pays clinical-trial expenses and receives data for regulatory filings in other territories; if Karveer Meditech commercializes there, NanoViricides receives royalties equal to 70% of sales net of costs to unaffiliated third parties.
A standby line of credit from President Anil Diwan has a maximum amount of $3,000,000 at a fixed 12% interest rate; the company reported no draw as of June 30, 2026.
NanoViricides, Inc. (NNVC) has filed a resale prospectus covering up to 2,516,339 shares of common stock issuable upon exercise of outstanding common stock purchase warrants held by a selling stockholder. The warrants have an exercise price of $1.75 per share and were issued in a July 24, 2026 registered direct offering.
The company is not selling any shares in this prospectus and will not receive proceeds from resales by the selling stockholder. NanoViricides would receive up to approximately $4.4 million in gross proceeds only if all common warrants are exercised for cash, which may or may not occur. As of August 21, 2026, there were 25,527,353 shares of common stock outstanding, which would rise to 28,043,692 shares assuming full warrant exercise. The company has no products or revenues, is a clinical-stage antiviral drug developer with lead candidate NV-387 ready for Phase II trials, and its common stock trades on NYSE American under the symbol NNVC at a last reported price of $1.34 on August 19, 2026.
NanoViricides, Inc. (NNVC) has filed a Form S-3 registering for resale up to 2,516,339 shares of common stock issuable upon exercise of outstanding Common Stock Purchase Warrants held by a selling stockholder. The warrants have an exercise price of $1.75 per share and were issued in a July 24, 2026 registered direct offering.
NanoViricides is not selling any shares in this transaction and will receive no proceeds from resales by the selling stockholder. The company would receive up to approximately $4.4 million in gross proceeds only if all such warrants are exercised for cash.
Common shares outstanding were 25,527,353 as of August 21, 2026, rising to 28,043,692 assuming full exercise of these warrants. NanoViricides is a clinical-stage antiviral developer with no revenues to date, and its most recent audited financial statements include an auditor’s explanatory paragraph about substantial doubt regarding its ability to continue as a going concern.
NanoViricides, Inc. entered into a securities purchase agreement with a single investor for a registered direct offering, selling 2,416,339 shares of common stock at $1.53 per share and pre-funded warrants for 100,000 shares at $1.52999, together with common warrants to purchase 2,516,339 shares at an exercise price of $1.75.
The pre-funded warrants are immediately exercisable at $0.00001 per share, while the common warrants become exercisable six months after issuance and expire five and one-half years from that date. The offering closed on July 27, 2026, generating approximately $3.8 million in gross proceeds before fees, to be used for working capital, capital expenditures, research and development, clinical trials, and potential acquisitions and other strategic purposes. The company agreed to a 60-day restriction on additional equity issuances (with limited exceptions), 30-day lock-ups for its chief executive officer and principal stockholder, and to file a resale registration for warrant shares within 30 days of closing, while paying a 7.0% placement fee and up to $50,000 of placement agent expenses.
NanoViricides, Inc. is conducting a registered direct offering of 2,416,339 shares of common stock at $1.53 per share and Pre-Funded Warrants to purchase up to 100,000 shares at $1.52999 each, together with Common Warrants to purchase up to 2,516,339 shares at an exercise price of $1.75 per share. Each Pre-Funded Warrant is immediately exercisable at $0.00001 per share; each Common Warrant becomes exercisable six months after issuance and expires five and one-half years from issuance.
Gross proceeds are expected to be $3,849,997.67, with a 7.0% placement fee of $269,499.91, yielding approximately $3,580,497.76 before other expenses and about $3,450,000 in estimated net proceeds. The company plans to use the funds for general corporate purposes, including working capital, capital expenditures, research and development, clinical trials, and potential acquisitions or other strategic purposes. Common stock outstanding is expected to increase to 25,499,155 shares after the offering, assuming exercise of the Pre-Funded Warrants but excluding the Common Warrants.
NanoViricides is a clinical-stage company with no approved products or revenues, significant accumulated losses, and a disclosed cash position that, together with other resources, does not fund at least 12 months of planned operations, leading management to state there is substantial doubt about its ability to continue as a going concern without additional financing.
NanoViricides, Inc. has amended its prospectus supplement for its at-the-market common stock offering program to reduce the maximum amount it may sell under its existing Form S-3 registration to $0 of common stock. This change reflects limits under General Instruction I.B.6 of Form S-3.
As of July 23, 2026, the company’s public float was $41,583,701, based on 22,356,829 non-affiliate shares at $1.86 per share, and it has sold approximately $9,843,165 of common stock under I.B.6 in the prior 12-month period. Under the amended terms, NanoViricides may not currently offer or sell additional shares through or to D. Boral Capital LLC under the At Market Issuance Sales Agreement. If its public float changes, the company may again conduct primary offerings on Form S-3 up to one-third of its public float, and if its public float rises above $75 million, the I.B.6 limitation would no longer apply.